Lipid nanoparticles (LNPs ... the company that developed the LNPs used in the Pfizer-BioNTech mRNA vaccine against SARS-CoV-2. She says it soon became clear that LNPs worked even better as ...

One avenue for new vaccine development is mucosal vaccines. In theory, dosing the vaccine directly into the respiratory tract ...

Five years later, we can tell the tale of using the tools of science, we were able to turn the tide on SARS-CoV-2 and ... which rely on lipid nanoparticles (LNPs) for mRNA protection and cellular ...

3 In addition to mRNA vaccines, potent antibody responses can also be elicited by protein-based vaccines, such as the Novavax NVX-CoV2373 vaccine, that present the SARS-CoV-2 spike protein on the ...

Labcorp stands out for its ability to deliver scientific expertise, perform more than 275,000 polymerase chain reaction (PCR) tests for SARS-CoV ... solved by use of lipid nanoparticle packaging.

The door may now be open for additional challenges to patents covering mRNA vaccine technologies, paving the way for increased competition in the ...

The SARS-CoV-2 virus, like all biological material, is composed of proteins, lipids, nucleic acids, metabolites and other small molecules. Researchers are using -omics technologies (e.g. proteomics, ...

The mRNA is protected by a lipid coating, like a fat bubble ... the cell produces spike proteins similar to those on the surface of SARS-CoV-2. Our immune system recognizes those vaccine-created ...

mRNA-encoded self-assembling enveloped virus-like particles presenting SARS-CoV-2 spike protein enhance immunity and ... he developed that combines features of mRNA and protein nanoparticle-based ...